Covalent Inhibitors of KEAP1 with Exquisite Selectivity

The NRF2-KEAP1 interaction is central for cytoprotection against stresses, giving it high clinical significance. Covalent modification of KEAP1 is an efficient approach, but the covalent inhibitors used in the clinic carry undesired side effects originating in their moderate selectivity. Starting with a phenotypic screen, we identified a new covalent inhibitor chemotype that was optimized to deliver a series of potent and highly selective KEAP1 binders. While the developed compounds showed both cellular and in vivo activity, upregulating antioxidant response element-dependent target genes, they showed no genotoxicity in vitro. The lead compound exhibited broad selectivity in activity-based protein profiling and showed no significant interaction with a panel of commonly studied receptors nor with a broad panel of kinases. The nature of its interaction with KEAP1 and the origin of its selectivity were revealed by X-ray crystallography.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2024-11-21
DOI
https://doi.org/10.1021/acs.jmedchem.4c02019
Citations
3
Primary Topic
Genomics, phytochemicals, and oxidative stress
Type
article
Field-Weighted Citation Impact
0.70
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Covalent Inhibitors of KEAP1 with Exquisite Selectivity

Petra Dunkel, Valérie Duvivier, Charlotte E. Manning, Klaus Seedorf et al.
3 citations
Journal of Medicinal Chemistry
Genomics, phytochemicals, and oxidative stress
0.70
article

Covalent Inhibitors of KEAP1 with Exquisite Selectivity

Petra Dunkel, Valérie Duvivier, Charlotte E. Manning, Klaus Seedorf, William Richardson, András Kotschy, Nicolas Provost, Philippe Delerive, Piroska Markacz, Miklós Nyerges, Cédric Vinson, Imre Fejes, Márió Gyuris, Csaba Wéber, Virginie Martiny, K. Huber, János Tatai, R. Chalk, Alex N. Bullock, Mónika Rudas, Elisabeth M. Rothweiler, Alexandra Bristiel, Jeppe Tranberg-Jensen, Melissa N. Sweeney, Brice Vidal, Andras Herner
article en
3 citations

Abstract

The NRF2-KEAP1 interaction is central for cytoprotection against stresses, giving it high clinical significance. Covalent modification of KEAP1 is an efficient approach, but the covalent inhibitors used in the clinic carry undesired side effects originating in their moderate selectivity. Starting with a phenotypic screen, we identified a new covalent inhibitor chemotype that was optimized to deliver a series of potent and highly selective KEAP1 binders. While the developed compounds showed both cellular and in vivo activity, upregulating antioxidant response element-dependent target genes, they showed no genotoxicity in vitro. The lead compound exhibited broad selectivity in activity-based protein profiling and showed no significant interaction with a panel of commonly studied receptors nor with a broad panel of kinases. The nature of its interaction with KEAP1 and the origin of its selectivity were revealed by X-ray crystallography.

Journal of Medicinal ChemistryVol. 67(23)
Angkor Hospital for Children (KH), Nuffield Orthopaedic Centre (GB), University of Oxford (GB), Servier (France) (FR), Institut des Hautes Études Scientifiques (FR)
Openalex Percentile: Top 29%
Genomics, phytochemicals, and oxidative stress
0.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.